Caris Life Sciences Cash Flow Statement
NASDAQ: CAIHealth CareMedical SpecialitiesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Caris Life Sciences free cash flow
In fiscal 2025, Caris Life Sciences generated $83.2 million of operating cash flow and spent $16.3 million on capital expenditures. That left free cash flow of $66.9 million, a free-cash-flow margin of 8.2% of revenue. Caris Life Sciences returned $113,000 to shareholders through share repurchases, equal to 0% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Caris Life Sciences cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Net Income | -68.09M | -281.89M | -341.42M |
| Net Income growth (YoY) | — | — | — |
| Depreciation & Amortization | 22.61M | 48.91M | 49.00M |
| Stock-Based Compensation | 70.01M | 18.64M | 15.24M |
| Change in Working Capital | -12.43M | -34.65M | -2.11M |
| Operating Cash Flow | 83.16M | -245.20M | -276.10M |
| Capital Expenditures | -16.26M | -8.44M | -22.32M |
| Investing Cash Flow | -16.26M | 52.93M | 214.77M |
| Share Repurchases | -113.00K | 0 | 0 |
| Financing Cash Flow | 664.99M | 200.29M | 10.13M |
| Net Change in Cash | 732.01M | 8.02M | -51.13M |
| Free Cash Flow | 66.89M | -253.64M | -298.42M |
This table shows 3 annual periods of Caris Life Sciences's cash flow statement, from FY 2025 back to FY 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CAI's reporting calendar. What is a cash flow statement?